# KN046 in Subjects With Advanced Solid Tumors and Lymphoma

> **NCT03733951** · PHASE1 · COMPLETED · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 139 (actual)

## Conditions studied

- Advanced Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** KN046

## Key facts

- **NCT ID:** NCT03733951
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-18
- **Primary completion:** 2023-01-03
- **Final completion:** 2023-02-02
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733951, "KN046 in Subjects With Advanced Solid Tumors and Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03733951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*